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Abstract
Background
Remission has been identified as a top priority by people with type 2 diabetes. Remission is
commonly used as an outcome in research studies; however, a widely accepted definition of
remission of type 2 diabetes is lacking. A report on defining remission was published (but
not formally endorsed) in Diabetes Care, an American Diabetes Association (ADA) journal.
This Diabetes Care report remains widely used. It was the first to suggest 3 components
necessary to define the presence of remission: (1) absence of glucose-lowering therapy
(GLT); (2) normoglycaemia; and (3) for duration�1 year. Our aim is to systematically review
how remission of type 2 diabetes has been defined by observational and interventional stud-
ies since publication of the 2009 report.
Methods and findings
Four databases (MEDLINE, EMBASE, Cochrane Library, and CINAHL) were searched for
studies published from 1 September 2009 to 18 July 2020 involving at least 100 participants
with type 2 diabetes in their remission analysis, which examined an outcome of type 2 diabe-
tes remission in adults�18 years and which had been published in English since 2009.
Remission definitions were extracted and categorised by glucose-lowering therapy, glycae-
mic thresholds, and duration. A total of 8,966 titles/abstracts were screened, and 178 stud-
ies (165 observational and 13 interventional) from 33 countries were included. These
contributed 266 definitions, of which 96 were unique. The 2009 report was referenced in 121
(45%) definitions. In total, 247 (93%) definitions required the absence of GLT, and 232
(87%) definitions specified numeric glycaemic thresholds. The most frequently used thresh-
old was HbA1c<42 mmol/mol (6.0%) in 47 (20%) definitions. Time was frequently omitted.
In this study, a total of 104 (39%) definitions defined time as a duration. The main limitations
of this systematic review lie in the restriction to published studies written in English with sam-
ple sizes of over 100. Grey literature was not included in the search.
Conclusions
We found that there is substantial heterogeneity in the definition of type 2 diabetes remission
in research studies published since 2009, at least partly reflecting ambiguity in the 2009
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report. This complicates interpretation of previous research on remission of type 2 diabetes
and the implications for people with type 2 diabetes. Any new consensus definition of remis-
sion should include unambiguous glycaemic thresholds and emphasise duration. Until an
international consensus is reached, studies describing remission should clearly define all 3
components of remission.
Systematic review registration
PROSPERO CRD42019144619
Author summary
Why was this study done?
• Remission of type 2 diabetes is very important to people with type 2 diabetes, but there
is no single agreed definition of remission.
• Varying definitions of remission make research findings inconsistent and make remis-
sion difficult to effectively use as a target in clinical care.
What did the researchers do and find?
• We systematically reviewed 178 research studies with an outcome of type 2 diabetes
remission that had been published between 2009 and 2020 to evaluate how remission of
type 2 diabetes had been defined.
• There were 96 unique definitions of type 2 diabetes remission, with substantial
heterogeneity.
• A total of 93% of type 2 diabetes remission definitions stated that all glucose-lowering
therapy (GLT) should be stopped. Moreover, 87% included a numeric glycaemic
threshold, but the exact threshold and combination of tests to measure normal gly-
caemic levels varied considerably. In total, 61% did not include duration of stopping
therapy or normal glycaemic levels as part of the definition of type 2 diabetes
remission.
What do these findings mean?
• The heterogeneity of type 2 diabetes remission definitions in the recent research litera-
ture highlights a fundamental problem for remission research.
• Synthesising the findings of studies of remission will be limited by variation in defini-
tion. Future meta-analyses should ideally use individual participant data.
• Categorising people into remission and non-remission groups in a way that is consistent
with the current type 2 diabetes diagnosis guidelines is challenging and should be care-
fully considered before integrating remission with clinical type 2 diabetes management
pathways.
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• Researchers should always clearly and unambiguously state their definition of remis-
sion. There is a clear need for an internationally accepted and routinely implemented
definition of remission.
Introduction
Type 2 diabetes is a global health priority [1]. By 2045, an estimated 629 million people will be
affected by diabetes, of whom 90% to 95% will have type 2 diabetes [1]. Drivers for the twin
epidemics of obesity and diabetes lie in complex interactions between obesogenic environ-
ments, a biological tendency for weight gain, and an ageing population [2,3]. The rapid spread
of obesity and diabetes worldwide has considerable health implications for the individual and
major financial consequences for health services [3]. In 2015, the global economic burden of
diabetes was estimated to be US$1.3 trillion [4], and total costs are estimated to rise to US$2.2
to $2.5 trillion by 2030 [4]. Type 2 diabetes has conventionally been considered a lifelong, pro-
gressive disease [5]. The concept of reversing type 2 diabetes by metabolic surgery was intro-
duced in the early 1990s [6]. Buchwald and colleagues strengthened this concept by defining
and demonstrating the resolution of clinical and laboratory manifestations of type 2 diabetes
in their 2004 and 2009 systematic reviews and meta-analyses [7,8]. While such research groups
did not publish any guidance on defining resolution of diabetes, their definitions of resolution
developed for use in review and meta-analysis were widely adopted [9]. In 2009, a multidisci-
plinary expert group published a consensus report (2009 report) in Diabetes Care, an Ameri-
can Diabetes Association (ADA) journal to provide guidance on defining this concept [10],
although this 2009 report does not represent the official ADA position [11]. The 2009 report
recommends that the term “remission” should be applied to a chronic disease such as diabetes,
rather than terms like “resolution.” It broadly defines remission as “achieving glycaemia below
the diabetic range in the absence of active pharmacologic or surgical therapy” [10] (p. 2134).
Three specific types of remission are then explicitly defined: partial remission, complete remis-
sion, and prolonged remission (cure) (Table 1). Each remission type is composed of 3 compo-
nents: (1) the absence of glucose-lowering therapy (GLT), (2) the achievement of a glycaemic
threshold, and (3) a duration during which the other 2 components have to be sustained for
remission to have occurred. The 2009 report is not to be confused with the annually updated
ADA Standards of Care, which contains the official ADA position on the diagnosis of diabetes
and prediabetes [12]; as yet, there is no official ADA position or internationally agreed consen-
sus on the definition of remission [12].
Remission of type 2 diabetes is of increasing interest to professionals and patients [12]. Two
recent trials in the United States of America and United Kingdom have demonstrated cost-
effective remission of type 2 diabetes through intensive lifestyle measures such as very low-cal-
orie diets [13,14]. These have reignited interest (particularly among people living with diabetes
and their carers) [15] into whether remission might be a realistic goal for some people with
type 2 diabetes and an additional strategy for health services. This issue is difficult to address
when there is no official international consensus on how to define remission [16]. In the UK,
the Primary Care Diabetes Society and the Association of British Clinical Diabetologists
responded by publishing a consensus in 2019 which states that “remission can be achieved
when a person with type 2 diabetes achieves 1. Weight loss; 2. HbA1c<48mmol/mol (6.5%) or
FPG<7.0mmol/l (126mg/dL) on two occasions separated by six months; 3. Following
PLOS MEDICINE Defining remission of type 2 diabetes in research studies: A systematic scoping review
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003396 October 28, 2020 3 / 16
complete cessation of all GLT.” [17] (p. 74). The International Diabetes Federation discusses
remission in the context of bariatric surgery in their 2017 clinical practice recommendations
for primary care, where they state “Remission is defined by most guidelines as an HbA1c
below 6% (42mmol/mol) without medication for 6 months or more” [18] (p. 21). Consensus
discussions are ongoing as part of the response to calls for an international consensus on defi-
nition [16]. However, it is unclear how remission is currently being interpreted in research lit-
erature. The aim of this study is to systematically review how remission of type 2 diabetes has
been defined by observational and interventional studies since the publication of the 2009
report, in order to contribute to developing future consensus on defining type 2 diabetes
remission.
Methods
Search strategy and selection criteria
We adapted the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement for scoping reviews to report our systematic review of observational and
interventional studies [19] (S1 Table). We included observational and interventional studies
involving at least 100 participants with type 2 diabetes in their remission analysis, which exam-
ined an outcome of type 2 diabetes remission in adults�18 years old, and which had been
published in English since 2009 (when the 2009 report was published) [10]. These restrictions
were decided a priori and were expected to provide a sufficient number of papers specifically
focussing on the effect of the 2009 report in reasonably large research studies within our time
and resource constraints (S2 Table). Web content or materials produced outside the tradi-
tional academic publishing were not searched as we were interested in how remission was
defined in manuscripts that had been peer-reviewed in academic publication and distribution
channels. We excluded case reports, systematic reviews, protocols, or reviews. Studies focus-
sing on prediabetes, impaired glucose tolerance, impaired fasting glucose, gestational diabetes,
maturity onset diabetes of the young, steroid-induced diabetes, or type 1 diabetes were
excluded as beyond the scope of this review (S2 Table).
Table 1. 2009 report recommendation for defining remission of diabetes and possible interpretations of recommendations (adapted from Buse, 2009) [10].
Remission term GLT Glycaemic threshold Time (years)
Unspecified
remission
Broadly defined in main text as “achieving glycemia below the diabetic range in the absence of active pharmacologic (anti-hyperglycemic
medications, immunosuppressive medications) or surgical (ongoing procedures such as repeated replacements of endoluminal devices)
therapy. A remission can be characterized as partial or complete.” [10] (p. 2134)
Partial remissiona No active pharmacologic therapy (or ongoing
procedures)
Hyperglycaemia below diagnostic thresholds for
diabetesd
At least 1 year duration
Complete remissionb No active pharmacologic therapy (or ongoing
procedures)
Normal glycaemic measuresd At least 1 year duration
Prolonged remissionc No active pharmacologic therapy (or ongoing
procedures)
Normal glycaemic measuresd At least 5 years
duration
a Partial remission is specifically defined as “Sub-diabetic hyperglycaemia (HbA1c not diagnostic of diabetes <48mmol/mol (<6.5%), fasting glucose 5.6–6.9 mmol/l
(100–125 mg/dL)) of at least 1 year’s duration in the absence of active pharmacologic therapy or ongoing procedures.” [10] (p. 2134)
b Complete remission is specifically defined as “A return to ‘normal’ measures of glucose metabolism (A1C in the normal range, fasting glucose <5.6 mmol/l (<100 mg/
dl)) of at least 1 year’s duration in the absence of active pharmacologic therapy or ongoing procedures.” [10] (p. 2134)
c Prolonged remission is specifically defined as “Complete remission that lasts for more than 5 years and might operationally be considered a cure.” [10] (p. 2134)
d There is ambiguity in terms of whether remission requires HbA1c<threshold AND FPG<threshold or whether the logic is HbA1c<threshold OR FPG<threshold
(see footnotes a–c where the join between HbA1c and FPG is a comma rather than a logical operator).
FPG, fasting plasma glucose; GLT, glucose-lowering therapy.
https://doi.org/10.1371/journal.pmed.1003396.t001
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Patients or the public were not involved in the design, conduct, reporting, or dissemination
plans of our research. The Diabetes UK–James Lind Alliance Priority Setting Partnership has
recently identified remission as the top shared priority among people living with diabetes and
their carers, healthcare professionals, and black and minority ethnic groups [15].
We searched MEDLINE, EMBASE, CINAHL, and the Cochrane Library from 1 January
2009 to 18 July 2020 (S2 Table). The participants, interventions, comparisons, outcomes, and
study design (PICOS) search strategy [20] was developed with a senior librarian and combined
terms for “remission,” AND “type 2 diabetes,” AND “weight loss strategies,” AND “limits spec-
ified” (human patients, English language) (S3 Table). Two reviewers (MC and one of BG, SW,
and RP) independently screened all title and abstracts and all full texts against our inclusion
criteria using Covidence systematic review software (Veritas Health Innovation, Melbourne,
Australia). MC and RP independently extracted data in duplicate to a piloted Microsoft Excel
extraction form. In all cases, disagreement was discussed, and a third reviewer was involved to
resolve these if needed. The systematic review protocol was prespecified and prospectively reg-
istered (PROSPERO registration: CRD42019144619).
Outcomes
The primary outcome was the definition of remission used in each study irrespective of the
term(s) used to name the outcome (partial, complete, or prolonged remission and synonyms
such as resolution, cure, or reversal). Since an individual study could measure remission in
more than 1 way, we extracted data for all distinct definitions used in each paper.
Data analysis
For each definition of remission given by an underlying study, we sought to specify how each
of the 3 components of remission defined by the 2009 report was operationalised (absence of
GLT, normoglycaemia, and duration of 1 or both of absence of GLT and normoglycaemia),
irrespective of whether they referenced the 2009 report [10]. For each definition, we recorded
whether any components were omitted and quantified the heterogeneity within each compo-
nent by counting the number of unique ways each component was defined. We mapped every
definition extracted to the 3 types of remission initially introduced by the 2009 report (partial
remission, complete remission, and prolonged remission) based on the term used by the
authors. Where it was not possible to map to 1 of the 3 types, for example, authors used general
terms such as remission or resolution, we categorised a definition as unspecified remission.
We also counted the number of unique definitions across all definitions, regardless of the term
used by authors. We examined how the 2009 report defined remission and listed feasible inter-
pretations for each definition. We calculated the proportions of studies that cited the 2009
report, attempted to quantify fidelity to the 2009 report, and whether studies justified their par-
ticular interpretation. Assessing the methodological quality and risk of bias of included studies
in terms of the effect of their intervention on remission was not relevant to our aims or out-
comes. Assessing whether poor reporting of remission definitions was linked to high risk of
bias was outside the scope of this preliminary exploration. Therefore, we did not undertake
risk of bias assessment of the underlying studies in relation to the analysis they did.
Results
The search identified 8,966 citations, and 6,772 title and abstracts underwent screening after
removal of duplicates. After screening of 381 full texts against inclusion criteria, 178 studies
from 33 countries met the inclusion criteria (Fig 1), comprising 164 cohort studies, 11 rando-
mised controlled trials, 2 cluster randomised trials, and 1 cost-effectiveness model (S4 Table).
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Surgical interventions were the focus of 164 (93%) studies compared to 8 (4%) pharmacologi-
cal and 5 (2%) lifestyle interventions. One epidemiological study investigated the incidence of
remission in adults in a diabetes registry [21]. The 2009 report was referenced in 70 (39%)
studies and in 121 (45%) definitions. A total of 34 (19%) studies used an alternative or addi-
tional reference. Of the 18 alternative references, different versions of the ADA diagnostic
guidelines for diabetes [12] or Brethauer and colleagues [22] were used most frequently (S4
Table). In total, 81 (46%) studies did not directly reference an existing guideline or paper.
Variation in nomenclature and definition of remission
A total of 177 (99%) studies included 1 or more explicit definitions of remission, using 10 dif-
ferent terms: “partial remission,” “complete remission,” “prolonged remission,” “sustained
remission,” “sustained remission of hyperglycaemia,” “persistent remission of hyperglycae-
mia,” “any remission of hyperglycaemia,” “remission,” “resolution” and “cure” (S4 Table). We
combined definitions named as remission, remission of hyperglycaemia, and resolution into a
single category (unspecified remission) and definitions named as prolonged remission and
cure into a single category (prolonged remission) to create 4 groups. There were 266 distinct
definitions extracted, since 61 (34%) studies examined more than 1 remission type (for exam-
ple, separately defining partial remission and complete remission). Almost half of definitions
were categorised as unspecified remission (124 definitions (47% of all definitions)) compared
to the more specific terms partial remission (57 definitions (21%)), complete remission (64
definitions (24%)), and prolonged remission (21 definitions (8%)) (Table 2).
Glucose-lowering therapy
The GLT component of remission definitions was the most consistently defined. In total, 254
(95%) definitions included a GLT component, with 247 (93%) requiring the absence of GLT
and 8 definitions (3%) allowing continued use of GLT (either metformin or “some GLT”) in
their definition of remission (Table 2, Fig 2) [23–29]. One study specified that metformin pre-
scribed for a non-type 2 diabetes indication, e.g., polycystic ovarian syndrome (PCOS), need
not be stopped for remission to be achieved [29].
Fig 1. PRISMA diagram showing selection of studies. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
https://doi.org/10.1371/journal.pmed.1003396.g001
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Glycaemic thresholds
In this study, a total of 232 (87%) definitions specified numeric glycaemic thresholds (Table 2),
but with considerable heterogeneity. There were 25 unique numeric definitions of glycaemic
threshold in unspecified remission definitions, 8 in partial remission, 11 in complete remis-
sion, and 9 in prolonged remission (Fig 2, Table 3). HbA1c was used more often than fasting
plasma glucose (FPG) and 2-hour plasma glucose (2-hr PG). Of the 232 definitions that explic-
itly specified a numeric glycaemic threshold, 105 (45%) were based on HbA1c alone, and
HbA1c<42 mmol/mol (6.0%) was used most frequently in 47 (20%) definitions. HbA1c<48
mmol/mol (6.5%) with or without normoglycaemic interpretations of FPG (103 definitions)
and HbA1c<42 mmol/mol (6.0%) with or without normoglycaemic interpretations of FPG
(89 definitions) were the most frequently used thresholds (S5 Table). It was not clear whether
both or either of FPG and HbA1c needed to be attained in 23 definitions (S5 Table). There
were 27 unique ways to categorise normoglycaemia (when all categories of remission type
were merged, regardless of the term used by the authors) due to variation in the glycaemic
thresholds for each of HbA1c, FPG, and 2-hr PG and also the combination of glycaemic tests
specified (S5 Table).
Time
The time component was the most poorly reported component of remission definitions. It was
always specified in definitions of prolonged remission but not specified in 72 (58%) of unspeci-
fied remission definitions, 20 (35%) of partial remission definitions, and 25 (41%) of complete
remission definitions (Table 3, Fig 2). When specified, the time periods defining duration of
normoglycaemia ranged from 30 days to 5 years (Fig 2), with 17% of definitions defining time
cross-sectionally (e.g., assessing remission at one moment in time such as at 1 year follow-up
after an intervention) rather than longitudinally (e.g., absence of GLT and glycaemic threshold
definitions met for a duration of 1 year) (Table 2). Eleven studies (13 definitions) specified a
time period or follow-up of less than 1 year in their definitions [13,23,25,30–37] (Fig 2). We
found 13 unique definitions for the time component (when all categories of remission type
Table 2. Definition of remission in terms of GLT, time, and glycaemic threshold components for all 266 definitions of remission citeda.
All 3 components
definedb n (%)
GLT Glycaemic threshold Time
Absence of GLT
specified n (%)
Explicit numeric threshold
specified n (%)
Defined cross-
sectionallyc n (%)
Defined longitudinallyd
n (%)
Unspecified remission 124
definitions (57 unique)
45 (36.3) 116 (93.5) 95 (76.6) 19 (15.3) 34 (27.4)
Partial remission 57 definitions
(22 unique)
34 (59.6) 49 (86.0) 54 (94.7) 9 (15.7) 28 (49.1)
Complete remission 64
definitions (25 unique)
38 (59.4) 61 (95.3) 62 (96.9) 12 (18.8) 27 (42.2)
Prolonged remission 21
definitions (11 unique)
21 (100) 21 (100) 21 (100) 6 (28.6) 15 (71.4)
Total: 266 definitions (96
unique)
138 (51.9) 247 (92.9) 232 (87.2) 46 (17.3) 104 (39.1)
a Studies can contribute more than 1 definition of remission, for example, because they measure both complete remission and partial remission.
b Glycaemic threshold had to be defined with an explicit numeric threshold.
c Assessing remission at one moment in time such as at 1 year follow-up after an intervention.
d Assessing remission after criteria have been met for a duration of time.
GLT, glucose-lowering therapy.
https://doi.org/10.1371/journal.pmed.1003396.t002
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were merged, regardless of the term used by the authors) (Fig 2, Table 3). This was due to vari-
ation in the period of time specified, definition of time cross-sectionally or longitudinally, and
applying a different definition of time to the other 2 remission components (Fig 2).
Unique definitions
Overall, there were 96 unique definitions of remission. There were 57 unique definitions of
unspecified remission, 22 unique definitions of partial remission, 25 unique definitions of
complete remission, and 11 unique definitions of prolonged remission (Table 2, Fig 2). For
each remission category, heterogeneity in defining glycaemic thresholds was the most frequent
driver of total heterogeneity (Table 3, S1–S4 Figs).
Discussion
Since the publication of the 2009 report, our analysis of 178 studies conducted in 33 countries
identified substantial heterogeneity in how remission is named and defined. We identified 96
Fig 2. Sankey diagrams showing heterogeneity in definitions of remission. (A) Unspecified remission. (B) Partial remission. (C) Complete remission. (D)
Prolonged remission. Red indicates a definition that has 1 or more missing (i.e., undefined or ambiguously defined) component. GLT, glucose-lowering
therapy.
https://doi.org/10.1371/journal.pmed.1003396.g002
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unique definitions of remission that reflected heterogeneity in the 3 components relating to
GLT (3 unique explicit definitions), glycaemic thresholds (27 unique numeric definitions),
and time (13 unique explicit definitions), as well as heterogeneity in different combinations of
these 3 components in each definition. The 2009 report was the most widely used guide in
defining remission and was referenced in 121 (45%) definitions.
To our knowledge, this is the first review to systematically categorise and quantify heteroge-
neity of remission definitions in recent research. Previous studies have shown that the choice
of glycaemic thresholds in remission definitions markedly affects the estimates of the propor-
tion of people in remission [9,38–42]. Despite a variety of strategies to manage heterogeneous
definitions of remission, systematic reviews have acknowledged the limitations of summaris-
ing data from primary remission studies and interpreting pooled estimates [43–46]. Our find-
ings confirm and quantify the substantial heterogeneity and ambiguity in defining the
glycaemic component of remission. We additionally identify that the inconsistent definition of
time creates further heterogeneity.
Strengths of the study include systematic searching and that all screening and extraction
was carried out independently by 2 reviewers. We used the PRISMA statement for scoping
reviews to ensure clarity of reporting [19]. We had to adapt traditional PRISMA recommenda-
tions for a review assessing and evaluating a particular aspect of methodology (how remission
was defined) rather than a traditional outcome-focussed systematic review. Potential limita-
tions include the restriction to studies with sample sizes of over 100 and not searching for grey
literature or performing a forward citation search. The review still included 178 studies with
considerable heterogeneity in remission definition, but these limitations may have introduced
bias. For example, smaller studies may have been carried out by practising clinicians who may
Table 3. Unique definitions for remission in terms of GLT, glycaemic threshold component, and time components for all 266 definitions of remissions cited.
No. (%) of definitions which
did not clearly specify each
component
GLT component No.
of unique definitions
Glycaemic threshold No.
of unique numeric
definitions
Time component No.
of unique definitions
Full definition No. of
unique definitions
Unspecified remission
(n = 124 definitions)
GLT absence 6 (4.9) 2 25 11 57
Glycaemia 29 (23.4)a
Time 72 (58.1)
Partial remission (n = 57
definitions)
GLT absence 3 (5.3) 2 8 5 22
Glycaemia 3 (5.3)b
Time 20 (35.1)
Complete remission
(n = 64 definitions)
GLT absence 2 (3.1) 2 11 5 25
Glycaemia 2 (3.1)c
Time 25 (40.6)
Prolonged remission
(n = 21 definitions)
GLT absence 0 1 9 2 11
Glycaemia 0
Time 0
Total unique definitions
(regardless of remission
term)d
GLT absence 11 (4.1) 3 27 13 96
Glycaemia 34 (12.8)
Time 117 (44.0)
a A total of 13 (10.5%) definitions were missing, and 16 (12.9%) definitions were ambiguous as they did not state a numeric threshold.
b A total of 3 (5.3%) definitions were ambiguous as they did not state a numeric threshold.
c A total of 2 (3.5%) definitions were ambiguous as they did not state a numeric threshold.
d Unique definitions merged across categories. Due to overlap in unique definitions when subcategories were merged, total is less than the sum of unique categories in
each subcategory of remission.
GLT, glucose-lowering therapy.
https://doi.org/10.1371/journal.pmed.1003396.t003
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have used different definitions of remission to large research studies. However, the likely direc-
tion of any bias is towards underestimating true heterogeneity in defining remission, so we do
not think our conclusions would change. In restricting to English-only manuscripts, we are
potentially limited in our ability to draw conclusions on international practice; however, our
included studies still demonstrate a good distribution of countries, so this decision may not
have unduly biassed the outcome of the study (S4 Table). In the registered protocol, 1 objective
was to evaluate fidelity to the 2009 report in studies citing it. However, while carrying out the
review, we identified that the glycaemic component of the 2009 report is itself ambiguous in
terms of (1) whether both or either FPG and HbA1c measures are required to determine nor-
moglycaemia; (2) what constitutes normal glycaemic thresholds for complete remission and
prolonged remission; and (3) whether remission is defined as a term in its own right. This pre-
cluded a meaningful analysis of fidelity (S6 Table). Some studies responded to this ambiguity
by discussing their interpretation and implementation of the 2009 report remission definitions
[21,41,47,48], while others [40,49–60] did not clarify whether both or either of FPG and
HbA1c were needed. The ambiguity in the 2009 report is likely to at least partly underlie the
heterogeneity we observed in the definition of remission.
The findings of this review have implications for research and identifies issues for future
consensus groups to consider. The 2009 report authors stated that they hoped their recom-
mendations would stimulate discussion, implying an expectation that their proposed remis-
sion definitions would evolve. A persisting problem is the difficulty in applying discrete binary
terms such as “remission” to a chronic disease characterised by glycaemia, which is a continu-
ous parameter [10,61]. Diagnostic thresholds for type 2 diabetes or prediabetes/intermediate
hyperglycaemia have shifted in response to different interpretations of the association between
glycaemia and vascular complications since the World Health Organization (WHO) first cre-
ated a framework to diagnose diabetes in 1965 [62]. This review highlighted a tendency or
preference in the research literature to use the word “remission” without qualification rather
than “partial,” “complete,” or “prolonged remission.” The complexity in defining remission
and creating partial and complete subcategories mirrors the complexity in defining diabetes
and prediabetes [12]/intermediate hyperglycaemia [62]. Complete remission mirrors the diag-
nosis of prediabetes which is in itself controversial and is not internationally consistent. We
therefore suggest the alternative terms “remission of type 2 diabetes” (instead of “partial remis-
sion”) and “remission of prediabetes” (instead of “complete remission”) to make this clear.
Creating and defining a remission of prediabetes category will be highly challenging (Table 4),
and it may be worth focussing on a consensus for remission of type 2 diabetes in the first
instance. There is an argument that combining multiple patient characteristics in a risk predic-
tion model may be an alternative approach that sidesteps the issue of creating and defining a
remission state and focusses instead on minimising future vascular complications rather than
attaining remission [61]. However, until such tools are created, clinicians rely upon naming
and classifying disease states that match diagnostic classification and coding schemas [63].
Future systematic reviews and meta-analyses would ideally use meta-analysis of individual par-
ticipant data to apply a consistent definition of remission to make best use of existing data.
The first step in translating research to clinical practice is to provide clinicians with guid-
ance on diagnosing type 2 diabetes remission. Given the fundamental difficulties in categoris-
ing type 2 diabetes, thought must be given to how remission guidelines maintain consistency
with diabetes diagnostic guidelines. Type 2 diabetes is diagnosed by HbA1c, or FPG, or 2-hr
PG. These continuous measures of glycaemia are categorised using the following thresholds:
HbA1c�48 mmol/mol (6.5%), FPG�7.0 mmol/l (126 mg/dL), and 2-hr PG�11.1 mmol/l
(200 mg/dL). As a consequence of diabetes diagnostic guidelines, the logical operator between
HbA1c, FPG, and 2-hr PG would ideally be AND. This would avoid the situation of a person
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diagnosed in remission from their type 2 diabetes based solely on an HbA1c<48 mmol/mol
(6.5%) (one of the most commonly used definitions of remission) while simultaneously meet-
ing criteria for diabetes diagnosis if their FPG was over 7.0 mmol/l (126 mg/dL) [12,64]. How-
ever, achieving remission in all 3 glycaemic measures has substantial time and cost
implications. This definition would be impractical to implement and would not be clinically
appropriate in all patients (e.g., HbA1c is an inaccurate measure of glycaemia in certain
patients and not easily available in all countries [64]) (Table 4).Therefore, using either HbA1c
or FPG or 2-hr PG approach may be the best compromise to define remission of type 2 diabe-
tes. Potential inconsistencies between diabetes diagnosis and remission diagnosis should, how-
ever, be specifically addressed in guidelines to avoid causing confusion among clinicians and
patients.
People with type 2 diabetes have prioritised remission of type 2 diabetes and want more
guidance about how to achieve remission and its implications [15]. This systematic review
focusses on how remission has been defined in the recent literature. In doing so, we have dem-
onstrated diverse multiple definitions of remission. If the concept of type 2 diabetes remission
is to be pursued and implemented in clinical practice, then proceeding without a widely
adopted consensus remission definition will be confusing for patients and clinicians alike. Het-
erogeneity also impedes research reproducibility, building knowledge, and the provision of
Table 4. Proposed alternative terms for remission of type 2 diabetes and remission of prediabetes/intermediate hyperglycaemia.
2009 report
category
Proposed category Possible definition for discussion
Partial remission Remission of type 2 diabetes 1. Absence of GLT required
Consensus required on GLT prescribed for non-diabetes indications, e.g., metformin for PCOS
2. Normoglycaemia thresholds for diabetes diagnosis as defined by WHO and ADA applied in reverse:
• HbA1c<48 mmol/mol (6.5%) [12,64] AND
• FPG<7.0 mmol/l (126 mg/dL) [12,62] AND
• 2-hr PG<11.1 mmol/l (200 mg/dL) [12,62]
Consensus is required on whether all available glycaemic tests must be normal given ADA and WHO
diagnostic guidelines or whether remission can be diagnosed based on the single most appropriate test for the
patient (e.g., HbA1c, FPG, or 2-hr PG). If only 1 test is required for remission, how to manage conflicting
glycaemic results, e.g., HbA1c<48 mmol/mol and FPG>7.0 mmol/l.
3. Absence of GLT and glycaemic thresholds both met for a “duration” of time
Consensus is required on the duration required, e.g., 6 months or 12 months.
Complete
remission
Remission of pre-diabetes/
intermediate glycaemia�
1. Absence of GLT required
Consensus required on GLT prescribed for non-diabetes indications, e.g., metformin for PCOS
2. Normoglycaemia thresholds used for prediabetes (ADA) or intermediate glycaemia (WHO) applied in
reverse:
• HbA1c threshold is disputed
(a) ADA: HbA1c <39 mmol/mol (5.7%) [12]
(b) WHO: insufficient evidence [64]
• FPG threshold is disputed
(a) ADA: <5.6 mmol/l (100 mg/dL) [12]
(b) WHO: <6.1 mmol/mol (110 mg/dL) [62]
• 2-hr PG<7.8 mmol/l (140 mg/dL) [12,62]
Consensus required on thresholds and whether all available glycaemic tests must be normal or whether
remission can be diagnosed based on the single most appropriate test for the patient
3. Absence of GLT and glycaemic thresholds both met for a duration of time
Consensus is required on the duration required, e.g., 6 months or 12 months.
� Prediabetes itself is a disputed concept, and a consensus definition for a remission of prediabetes/intermediate hyperglycaemia is likely to be very challenging. WHO
does not use the term prediabetes and suggests “intermediate glycaemia” which can include (1) impaired fasting glucose; FPG 6.1–6.9 mmol/l (110–124 mg/dL) and (if
measured) 2-hr PG<7.8 mmol/l (140 mg/dL) and (2) impaired glucose tolerance; FPG<7.0 mmol/l (126 mg/dL) and 2-hr PG�7.8 (140 mg/dL) and <11.1 mmol/l (200
mg/dL)) [62] (p. 3)
ADA, American Diabetes Association; GLT, glucose-lowering therapy; PCOS, polycystic ovarian syndrome; WHO, World Health Organization; 2-hour plasma glucose,
2-hr PG.
https://doi.org/10.1371/journal.pmed.1003396.t004
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clear guidance to people with type 2 diabetes. This review supports the need for an interna-
tional consensus definition of remission to guide both research and clinical practice. In the
meantime, any research study using “remission” as an outcome should unambiguously report
and justify their definition in terms of absence of GLT, glycaemic thresholds, and time.
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